全文获取类型
收费全文 | 89755篇 |
免费 | 6476篇 |
国内免费 | 2450篇 |
专业分类
耳鼻咽喉 | 509篇 |
儿科学 | 946篇 |
妇产科学 | 693篇 |
基础医学 | 4681篇 |
口腔科学 | 785篇 |
临床医学 | 7397篇 |
内科学 | 7038篇 |
皮肤病学 | 1007篇 |
神经病学 | 3200篇 |
特种医学 | 2125篇 |
外国民族医学 | 14篇 |
外科学 | 4111篇 |
综合类 | 14932篇 |
现状与发展 | 5篇 |
预防医学 | 10419篇 |
眼科学 | 1084篇 |
药学 | 26236篇 |
507篇 | |
中国医学 | 6786篇 |
肿瘤学 | 6206篇 |
出版年
2024年 | 221篇 |
2023年 | 1085篇 |
2022年 | 2560篇 |
2021年 | 3214篇 |
2020年 | 3300篇 |
2019年 | 2347篇 |
2018年 | 2376篇 |
2017年 | 2929篇 |
2016年 | 3603篇 |
2015年 | 3428篇 |
2014年 | 7120篇 |
2013年 | 7816篇 |
2012年 | 6285篇 |
2011年 | 6439篇 |
2010年 | 4865篇 |
2009年 | 4456篇 |
2008年 | 4362篇 |
2007年 | 4313篇 |
2006年 | 3651篇 |
2005年 | 3088篇 |
2004年 | 2487篇 |
2003年 | 2140篇 |
2002年 | 1742篇 |
2001年 | 1556篇 |
2000年 | 1349篇 |
1999年 | 1301篇 |
1998年 | 1006篇 |
1997年 | 918篇 |
1996年 | 809篇 |
1995年 | 801篇 |
1994年 | 746篇 |
1993年 | 602篇 |
1992年 | 600篇 |
1991年 | 498篇 |
1990年 | 490篇 |
1989年 | 435篇 |
1988年 | 448篇 |
1987年 | 362篇 |
1986年 | 327篇 |
1985年 | 415篇 |
1984年 | 368篇 |
1983年 | 243篇 |
1982年 | 268篇 |
1981年 | 193篇 |
1980年 | 183篇 |
1979年 | 158篇 |
1978年 | 146篇 |
1977年 | 135篇 |
1976年 | 138篇 |
1975年 | 122篇 |
排序方式: 共有10000条查询结果,搜索用时 326 毫秒
1.
2.
3.
目的探讨慢性泪囊炎患者应用鼻内镜下鼻腔泪囊造口术的临床效果及安全性。方法选取2018年1月至2019年12月因慢性泪囊炎于本院接受治疗的46例患者为研究对象,随机分为研究组与对照组,各23例。对照组接受泪囊鼻腔造口治疗,研究组取鼻内镜下鼻腔泪囊造口术治疗,比较两组临床效果、手术指标以及并发症发生情况。结果研究组治疗总有效率高于对照组(P<0.05);研究组术中出血量少于对照组,手术及住院时间均短于对照组(P<0.05);研究组并发症总发生率低于对照组(P<0.05)。结论慢性泪囊炎患者采用鼻内镜下鼻腔泪囊造口术治疗效果显著,并发症较少,安全性较高,值得临床推广应用。 相似文献
4.
《Vaccine》2022,40(42):6048-6054
BackgroundLive vaccines potentially have non-specific effects that protect against other infections than those the vaccines are targeted against. The national vaccination program (NVP) in Finland was changed on September 1st, 2006: before BCG vaccine was given to all newborn babies and afterwards to babies in risk groups only. We used this natural experiment to study the non-specific effects of BCG in the frame of NVP using before-after design.MethodsWe compared the incidence of several outcomes obtained from Finnish health registers between children born between July 1st, 2004, and June 30th, 2006 (BCG-eligible) and an age- and season-matched reference cohort born between July 1st, 2007, and June 30th, 2009 (BCG-non-eligible) using Poisson regression. These cohorts were restricted to full-term children whose parents were born in Finland. Follow-up began at birth and lasted 3 months, which is the scheduled age for DTaP-IPV-Hib vaccination, and from 4 months until first birthday. The outcomes included all infections, pneumonia and injuries as a negative control outcome.ResultsThe incidence rate ratio (IRR) of the BCG-eligible cohort (N = 93,658) compared to BCG-non-eligible cohort (N = 94,712) for hospital-diagnosed infections was 0.89 (95 %Cl 0.86–0.93) for the 3-month follow-up. The decrease was mainly caused by respiratory infections. In 4–12 months follow-up the BCG-eligible had slightly more infections than BCG-non-eligible children (IRR 1.03, 1.01–1.06).ConclusionsBCG vaccination was associated with a lower incidence of all hospital-diagnosed infections during the first three months of life. The difference cannot be attributed to lung tuberculosis, since only few paediatric cases occurred in Finland during 2000s. The disappearance of non-specific effect after administration of an inactivated vaccine is compatible with previous studies. 相似文献
5.
Karen Kayser Ariel Washington Lesley M. Harris Barbara Head 《Journal of psychosocial oncology》2021,39(1):17-34
Abstract
Purpose
Financial hardship can be a major cause of distress among persons with cancer, resulting in chronic stress and impacting physical and emotional health. This paper provides an analysis of the lived experience of cancer patients’ financial hardship from diagnosis to post-treatment. 相似文献6.
《Clinical genitourinary cancer》2022,20(5):442-451
IntroductionSelective internal radiation therapy (SIRT) is a potential treatment of primary renal cell carcinoma (RCC) deemed unsuitable for conventional therapy. RESIRT is the first-in-human study to evaluate safety and feasibility of SIRT for primary RCC.Patients and MethodsPatients with RCC, unsuitable for, or who declined conventional therapy, were eligible. A single transfemoral micro-catheter administration of yttrium-90 (Y-90) resin microspheres (SIR-Spheres) was delivered super selectively via the renal artery to the tumour at intended radiation doses of 75, 100, 150, 200, 300 Gy and a final cohort with a procedural endpoint of “imminent stasis,” in a dose-escalation design. Post-SIRT follow-up was 12 months. Study endpoints included safety and toxicity 30-days and 12-months post-SIRT and tumour response (RECIST v1.1).ResultsIn total, 21 patients were enrolled, mean (SD) age was 75 (9.3) years, WHO performance status was 0 in 81%, 12 (57%) had stage 3 chronic kidney disease, and 7 (33%) had prior contralateral nephrectomy. Overall, 71% of patients completed 12 months of follow-up. Intended doses were delivered without any dose-limiting toxicity. Seventeen out of 21 (81%) patients experienced an adverse event (AE) from any cause within 30 days post-SIRT; all SIRT-related AEs were grade 1 to 2. Best overall tumour responses were partial response 1/21 (4.8%), stable disease 19/21 (90.5%) and progressive disease 1/21 (4.8%).ConclusionThis study demonstrated good tolerability of SIRT at all dose levels including “imminent stasis” in treating primary tumours in RCC patients otherwise unsuitable for conventional therapy. SIRT with Y-90 resin microspheres may be a feasible treatment option for RCC. 相似文献
7.
《Research in social & administrative pharmacy》2022,18(9):3694-3698
In this paper, we argue that understanding and addressing the problem of poor-quality medical products requires a more interdisciplinary approach than has been evident to date. While prospective studies based on rigorous standardized methodologies are the gold standard for measuring the prevalence of poor-quality medical products and understanding their distribution nationally and internationally, they should be complemented by social science research to unpack the complex set of social, economic, and governance factors that underlie these patterns. In the following sections, we discuss specific examples of prospective quality surveys and of social science studies, highlighting the value of cross-sector partnerships in driving high-quality, policy-relevant research in this area. 相似文献
8.
9.
《中国现代医生》2020,58(8):65-67
目的 研究大剂量干扰素辅助治疗口腔黏膜恶性黑色素瘤的临床效果,探讨治疗应用的安全性。方法 选取我院于2017年11月~2018年11月收治的80例口腔黏膜恶性黑色素瘤患者作为研究对象,按照治疗方法不同分为两组,每组40例。对照组患者仅采用单纯手术治疗,治疗组在此基础上采用大剂量干扰素辅助治疗。观察两组患者生存情况、疾病复发情况以及毒副反应。结果 治疗组患者生存期限及无复发生存期明显长于对照组,治疗组复发率为5.00%,明显低于对照组的22.50%,差异有统计学意义(P0.05)。两组患者毒副反应比较差异无统计学意义(P0.05)。结论 口腔黏膜恶性黑色素瘤患者予以大剂量干扰素辅助疗法安全有效,值得临床推广。 相似文献
10.
发作性睡病是致残性白天睡眠增多的最常见原因之一,其治疗旨在减少白天睡眠增多和猝倒,改善夜间睡眠紊乱、睡眠瘫痪及与睡眠有关的幻觉。2019年,组胺H3受体拮抗剂替洛利生(Pitolisant)和多巴胺及去甲肾上腺素再摄取抑制剂索利氨酯(Solriamfetol)分别在欧盟和美国上市,前者具有促醒和抗猝倒作用,后者也有促醒作用,且戒断症状和滥用的发生率更低。目前,控释型羟丁酸钠(FT218)、低钠型羟丁酸盐(JZP-258)、选择性去甲肾上腺素再摄取抑制剂(瑞波西汀,又称AXS-12)以及莫达非尼联合氟卡尼制剂(THN102)等药物仍在开发和测试中,均可作为治疗发作性睡病相关白天睡眠增多和猝倒的潜在药物。本文重点介绍这些最近研发的发作性睡病治疗药物。 相似文献